Colloids and surfaces. B, Biointerfaces
Cure8 research brief
Why This Matters
Researchers are exploring new ways to deliver natural anti-inflammatory compounds to the colon; if the approach translates, it could inform future therapies aimed at reducing oxidative damage in ulcerative colitis.
Who Should Pay Attention
Researchers, translational scientists, nanomedicine developers, and clinicians following experimental IBD therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports an experimental preclinical study describing the design and testing of a copper–quercetin coordination nanocomposite intended to improve delivery and antioxidant activity of quercetin for ulcerative colitis.
The authors used network pharmacology and molecular docking to select quercetin, synthesized the nanocomposite, characterized its catalase-like and radical-scavenging activities in vitro, and tested therapeutic effects in a dextran sulfate sodium (DSS) mouse model of colitis.
In the animal model the nanocomposite-treated mice showed reduced colonic damage and a longer colon length compared with untreated DSS mice; the abstract reports measures of radical scavenging and colon length as part of the findings. The work is presented as a potential strategy for natural product–based nanotherapeutics rather than as a clinical treatment.
It is a laboratory and animal study that explores formulation, mechanism (antioxidant activity), and preliminary efficacy in mice.
Keep In Mind
Preclinical study: results are from in vitro assays and a DSS mouse model. The abstract reports promising antioxidant activity and reduced colonic injury in mice but does not provide human data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationColloids and surfaces. B, Biointerfaces
AuthorsZhan Y, Zuo L, Xie Y +8 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 17, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Quaternized chitosan-based double-network hydrogel for oral precise delivery of Sinapic acid in ulcerative colitis therapy.
The study describes a novel hydrogel designed to deliver sinapic acid directly to the inflamed colon and release drug in response to a reducing environment—an approach that could improve targeted oral therapies for...
Structural Characterization of a Glucan from Zingiber officinale and Its Efficacy in Alleviating Ulcerative Colitis by Ameliorating Gut Microbiota Imbalance
Researchers tested a ginger-derived glucan that reduced inflammation and reshaped the gut microbiota in a mouse colitis model — a potential prebiotic approach that could inform future IBD therapies or dietary strategies.
Chitosan-coated and sodium phytate-crosslinked porous starch microspheres for oral delivery of celastrol in colitis therapy.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...